NasdaqGS:PGNX

Stock Analysis Report

Executive Summary

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally.

Snowflake

Fundamentals

Exceptional growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Progenics Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.4%

PGNX

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-14.9%

PGNX

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: PGNX underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: PGNX underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

PGNXIndustryMarket
7 Day-6.4%1.6%0.4%
30 Day-10.8%-2.4%-1.2%
90 Day-7.8%-1.5%-0.4%
1 Year-14.9%-14.9%-6.9%-7.7%9.3%6.9%
3 Year-12.5%-12.5%14.7%10.7%45.8%36.4%
5 Year2.8%2.8%-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Progenics Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Progenics Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: PGNX ($4.85) is trading below our estimate of fair value ($15.02)

Significantly Undervalued: PGNX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PGNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PGNX is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Progenics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

62.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGNX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: PGNX is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: PGNX's loss is forecast to worsen by 0% next year.

Revenue vs Market: PGNX's revenue (45.1% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: PGNX's revenue (45.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: PGNX's Return on Equity is forecast to be very high in 3 years time (765.5%).


Next Steps

Past Performance

How has Progenics Pharmaceuticals performed over the past 5 years?

-36.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PGNX is unprofitable, and losses have increased over the past 5 years at a rate of -36.7% per year.

Accelerating Growth: Unable to compare PGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: PGNX has a negative Return on Equity (-106.56%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PGNX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PGNX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Progenics Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PGNX's short term assets ($100.2M) exceeds its short term liabilities ($23.6M)

Long Term Liabilities: PGNX's short term assets (100.2M) exceeds its long term liabilities (56.5M)


Debt to Equity History and Analysis

Debt Level: PGNX's debt to equity ratio (58%) is considered high

Reducing Debt: Insufficient data to determine if PGNX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: PGNX has a low level of unsold assets or inventory.

Debt Coverage by Assets: PGNX's debt is covered by short term assets (assets are 2.377280x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Progenics Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Progenics Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Mark Baker (64yo)

8.6yrs

Tenure

US$1,867,410

Compensation

Mr. Mark R. Baker, J.D. has been the Chief Executive Officer at Progenics Pharmaceuticals, Inc since March 2011 and served as its President from September 2009 to March 3, 2011. Mr. Baker served as a Secre ...


CEO Compensation Analysis

Compensation vs. Market: Mark's total compensation ($USD1.87M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.5yrs

Average Tenure

58yo

Average Age

Experienced Management: PGNX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

10.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: PGNX's board of directors are seasoned and experienced ( 10.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$359,73311 Sep 19
Velan Capital, L.P.
EntityCompany
Shares72,023
Max PriceUS$4.99
BuyUS$307,19309 Sep 19
Lte Partners, Llc
EntityCompany
Shares65,000
Max PriceUS$4.94
BuyUS$2,317,44605 Sep 19
Velan Capital, L.P.
EntityCompany
Shares521,038
Max PriceUS$4.51
BuyUS$878,60127 Aug 19
Velan Capital, L.P.
EntityCompany
Shares204,056
Max PriceUS$4.31
BuyUS$5,375,67626 Aug 19
Velan Capital, L.P.
EntityCompany
Shares1,266,472
Max PriceUS$4.78
BuyUS$526,70026 Aug 19
Lte Partners, Llc
EntityCompany
Shares125,000
Max PriceUS$4.21
BuyUS$4,776,96301 May 19
Velan Capital, L.P.
EntityCompany
Shares930,000
Max PriceUS$5.35
BuyUS$2,572,68401 May 19
Lte Partners, Llc
EntityCompany
Shares515,782
Max PriceUS$5.14
BuyUS$4,739,73205 Apr 19
Lte Partners, Llc
EntityCompany
Shares1,023,796
Max PriceUS$5.00
BuyUS$005 Apr 19
Velan Capital, L.P.
EntityCompany
Shares4,535,700
Max PriceUS$5.03
BuyUS$511,87805 Apr 19
Virinder Nohria
EntityIndividual
Shares110,000
Max PriceUS$4.73

Ownership Breakdown


Management Team

  • Mark Baker (64yo)

    CEO & Director

    • Tenure: 8.6yrs
    • Compensation: US$1.87m
  • Ben Osorio (62yo)

    Chief Operating Officer

    • Tenure: 0.6yrs
    • Compensation: US$967.41k
  • Pat Fabbio (51yo)

    Executive VP & CFO

    • Tenure: 3.9yrs
    • Compensation: US$974.15k
  • Vivien Wong (62yo)

    Executive Vice President of Development

    • Tenure: 0yrs
    • Compensation: US$1.02m
  • Asha Das (54yo)

    Chief Medical Officer

    • Tenure: 0.8yrs
  • Bryce Tenbarge (46yo)

    Senior Vice President of Commercial

    • Tenure: 1.5yrs
    • Compensation: US$869.06k
  • Jessica Jensen

    Senior Vice President of Clinical Development

    • Tenure: 1.5yrs
  • Melissa Downs

    Senior Manager of Investor Relations

    • Tenure: 0yrs

Board Members

  • Mark Baker (64yo)

    CEO & Director

    • Tenure: 8.6yrs
    • Compensation: US$1.87m
  • John Mendelsohn (82yo)

    Member of Cancer Scientific Advisory Board

    • Tenure: 0yrs
  • Steve Goff (67yo)

    Chairman of The Virology Scientific Advisory Board

    • Tenure: 28.5yrs
    • Compensation: US$119.76k
  • David Scheinberg (63yo)

    Director & Member of Cancer Scientific Advisory Board

    • Tenure: 23.8yrs
    • Compensation: US$237.16k
  • Nicole Williams (74yo)

    Independent Director

    • Tenure: 12.8yrs
    • Compensation: US$242.16k
  • Robin Weiss

    Member of Virology Scientific Advisory Board

    • Tenure: 0yrs
  • Sherie Morrison

    Member of Virology Scientific Advisory Board

    • Tenure: 0yrs
  • Brad Campbell (43yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$225.16k
  • Peter Crowley (60yo)

    Independent Chairman

    • Tenure: 9.3yrs
    • Compensation: US$452.75k
  • Karen Jean Ferrante (61yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$222.16k

Company Information

Progenics Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Progenics Pharmaceuticals, Inc.
  • Ticker: PGNX
  • Exchange: NasdaqGS
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$419.145m
  • Shares outstanding: 86.42m
  • Website: https://www.progenics.com

Number of Employees


Location

  • Progenics Pharmaceuticals, Inc.
  • One World Trade Center
  • 47th Floor
  • New York City
  • New York
  • 10007
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PGNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1997
PGPDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1997
0KOALSE (London Stock Exchange)YesCommon StockGBUSDNov 1997

Biography

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United St ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 23:40
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.